NASDAQ:COGT

Cogent Biosciences Stock Insider Trading

Healthcare > Biotechnology

Buy COGT

*Your capital is at risk

$32.26

-0.500 (-1.53%)

At Close: Jun 03, 2026

Cogent Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -77.72. In total, the insiders bought 25.9M and sold 12.03M COGT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-77.72
● Buy	25.9M shares
● Sell	12.03M shares
86% Buy Activity Strong Negative Correlation
Sell Signal High Confidence Mar 31, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -77.72. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Shegog Todd Director	Director	44 700 Value: $252.1K
Jun 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Ros Matthew Director	Director	44 700 Value: $252.1K
Jun 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Cain Christopher W. Director	Director	44 700 Value: $252.1K
Jun 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Ferrante Karen Jean Director	Director	44 700 Value: $252.1K
Apr 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Ferrante Karen Jean Director	Director	3 788 Value: $21.9K
Apr 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Ferrante Karen Jean Director	Director	3 788 Value: $21.9K
Jan 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Green John L. Chief Financial Officer	C-Suite Officer	270 000 Value: $2.40M
Jan 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Pinnow Cole Chief Commercial Officer	Officer	240 000 Value: $2.13M
Jan 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Robinson John Edward Chief Scientific Officer	Officer	270 000 Value: $2.40M
Jan 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Sachs Jessica Chief Medical Officer	Officer	270 000 Value: $2.40M
Jan 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Robbins Andrew R President And CEO	CEO / President	915 000 Value: $8.13M
Jan 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Kearns Evan Chief Legal Officer	Officer	230 000 Value: $2.04M
Jan 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Kearns Evan Chief Legal Officer	Officer	230 000 Value: $2.04M
Jan 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Robbins Andrew R President And CEO	CEO / President	915 000 Value: $8.13M
Jan 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Sachs Jessica Chief Medical Officer	Officer	270 000 Value: $2.40M
Jan 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Robinson John Edward Chief Scientific Officer	Officer	270 000 Value: $2.40M
Jan 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Pinnow Cole Chief Commercial Officer	Officer	240 000 Value: $2.13M
Jan 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Green John L. Chief Financial Officer	C-Suite Officer	270 000 Value: $2.40M
Jan 14, 2025 Buy	Common Stock P-Purchase	Pinnow Cole Chief Commercial Officer	Officer	43 750 Value: $332.4K
Jan 14, 2025 Buy	Common Stock P-Purchase	Pinnow Cole Chief Commercial Officer	Officer	43 750 Value: $332.4K
Jan 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Ferrante Karen Jean Director	Director	2 785 Value: $21.7K
Jan 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Ferrante Karen Jean Director	Director	2 785 Value: $21.7K
Oct 01, 2024 Buy	Stock Option (Right to Buy) A-Award	Ferrante Karen Jean Director	Director	2 034 Value: $21.9K
Oct 01, 2024 Buy	Stock Option (Right to Buy) A-Award	Ferrante Karen Jean Director	Director	2 034 Value: $21.9K
Jul 01, 2024 Buy	Stock Option (Right to Buy) A-Award	Ferrante Karen Jean Director	Director	2 462 Value: $22.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT COGENT BIOSCIENCES, INC.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon ...

Read Full Profile Here